US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

US lawmakers have intensified scrutiny of clinical trials conducted in China, focusing on trials at Chinese military hospitals and sites in Xinjiang due to ethical and national security concerns. The House Select Committee on China is investigating major drugmakers like Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb, demanding detailed information on their Chinese trial sites, data protection, and involvement with military-affiliated hospitals. The probe is part of broader efforts under the Biosecure Act and other legislative measures to restrict US ties with Chinese biotech firms. Industry leaders warn that these investigations could create significant distractions and financial burdens, potentially altering global drug development strategies and increasing costs for US companies.